

Le esperienze internazionali di adesione al test HPV e ai protocolli

Guglielmo Ronco
CPO Piemonte - Torino

GISCI

Gruppo Italiano Screening del Cervicocarcinoma

CONVEGNO NAZIONALE 2013

***LO SCREENING CERVICALE TRA PRESENTE E FUTURO
ACCOMPAGNARE IL CAMBIAMENTO***

23-24 Maggio 2013


Dati dalle survey dei progetti pilota

Manuel Zorzi

Registro Tumori del Veneto

ADESIONE ALL'INVITO

Programmi pilota con test HPV primario



Compliance to invitation by arm

Finnish trial


	HPV screening arm	Conventional screening arm
All ages	66410/101678 65.3%	65784/101747 64.7%
25-34	11191/20460 54.7%	11071/20455 54.1%
35-65	55219/81218 68.0%	54713/81292 67.3%

Table 2| Hazard ratios of invasive cervical cancer (ICC), AIS, or CIN among women invited for organised cervical screening in Finland, by screening status

	No of cases detected in women aged 25-34 years		No of cases detected in women aged ≥35 years		Hazard ratio (95% CI)		
	HPV screening arm	Conventional screening arm	HPV screening arm	Conventional screening arm	Age 25-34 years	Age ≥35 years	Overall
All women invited							
ICC	1	6	24	25	0.17 (0.02 to 1.39)	0.96 (0.55 to 1.68)	0.81 (0.48 to 1.37)
CIN 3 or AIS	90	70	158	119	1.29 (0.95 to 1.77)	1.33 (1.05 to 1.69)	1.32 (1.09 to 1.59)
CIN 2	209	135	236	155	1.56 (1.25 to 1.93)	1.53 (1.25 to 1.87)	1.54 (1.33 to 1.78)
CIN 1	117	68	175	123	1.73 (1.28 to 2.33)	1.43 (1.13 to 1.80)	1.53 (1.28 to 1.84)
Women who attended							
ICC	1	2	16	7	0.49 (0.04 to 5.42)	2.27 (0.93 to 5.51)	1.87 (0.83 to 4.20)
CIN 3 or AIS	62	32	116	77	1.92 (1.25 to 2.94)	1.50 (1.12 to 2.00)	1.62 (1.28 to 2.06)
CIN 2	155	85	190	116	1.81 (1.39 to 2.35)	1.63 (1.29 to 2.05)	1.71 (1.43 to 2.03)
CIN 1	88	43	138	84	2.03 (1.41 to 2.92)	1.63 (1.25 to 2.14)	1.77 (1.42 to 2.20)
Women who did not attend							
ICC	0	4	8	18	NA	0.45 (0.20 to 1.04)	0.37 (0.17 to 0.83)
CIN 3 or AIS	28	38	42	42	0.75 (0.46 to 1.23)	1.02 (0.66 to 1.56)	0.89 (0.65 to 1.23)
CIN 2	54	50	46	39	1.10 (0.75 to 1.62)	1.20 (0.78 to 1.84)	1.15 (0.86 to 1.52)
CIN 1	29	25	37	39	1.19 (0.69 to 2.02)	0.97 (0.62 to 1.52)	1.05 (0.75 to 1.48)

NA=not applicable. Association between age and ICC was not significant (P=0.83 among all invited, P=0.96 among women who attended, and P=0.12 among women who did not attend). Associations between age and CIN 1, CIN 2, and CIN 3 or AIS were significant (P<0.001 among all subgroups of attendance). There was significant effect modification between age and screening method only for CIN 1 among all women invited (P=0.002) and among women who attended (P=0.004).


Programmi pilota con test HPV primario



Programma	Campagna promozionale	Invito
Abruzzo	Nessuna	Lettera + depliant informativo
Guidonia	Solo primo round: campagne informative a livello comunale	Lettera + depliant informativo
Reggio Emilia	Su televisioni e su giornali locali	Lettera + depliant informativo
Torino	Nessuna	Lettera + depliant informativo
Trento	Iniziative nell'ambito del programma di aggiornamento sugli screening	Lettera + depliant informativo
Umbria	Campagna di promozione	Lettera + depliant informativo
Valcamonica		
Alta padova	Comunicazione a operatori (MMG, ginecologi)	Lettera + depliant informativo
Padova	Manifesti in consultori, studi MMG, farmacie	Lettera + depliant informativo
Este	Articolo su giornale locale Campagna di promozione in seconda fase	Lettera + depliant informativo
Rovigo	Articolo su giornale locale	Lettera + depliant informativo
Adria	Nessuna	Lettera + depliant informativo

Adesione all'invito

Survey su attività 2011



Pilot project design

- Centres: Torino, Trento & Reggio Emilia
- Cluster randomised (birth cohort) to HPV or cytology
- Age 35-64

Torino, Reggio Emilia e Trento: adesione all'invito

Centro	Invitate HPV	Aderenti HPV	Invitate citologia	Aderenti citologia	RR (95%CI)
Torino	66930	34209 (51.1%)	56666	28264 (49.9%)	1.02 (1.01-1.04)
Reggio Emilia	19826	11959 (60.3%)	17935	10554 (58.9%)	1.05 (1.03-1.07)
Trento	10748	6109 (56.8%)	8571	5928 (69.2%)	0.82 (0.80-0.84)
Totale	97504	52277 (53.6%)	83172	44746 (53.8%)	1.01 (0.99-1.03)*

* standardizzato per centro


Randomised Pilot Project Italy

Compliance to invitation


women invited within may 2012

Centre	Invited HPV	Compliance HPV	Invited cytology	Compliance cytology	RR (95%CI)
Torino	54123	27683 (51.1%)	45283	22751 (50.2%)	1.03 (1.01-1.04)
Reggio Emilia	16825	11678 (69.4%)	15338	9233 (60.2%)	1.15 (1.13-1.17)
Total	70948	39361 (55.5%)	60621	31984 (52.8%)	1.05 (1.06-1.06)


Adesione all'invito ai programmi pilota con HPV




Adesione: HPV vs Pap




VENETO - Adesione corretta all'invito



VENETO - Adesione corretta all'invito, per età




UMBRIA - Adesione all'invito per età




UMBRIA - Il peso dei solleciti

età	quota sollecitate	adesione senza sollecito
HPV	41,6	51,9
PAP	88,2	44,2


UMBRIA - Adesione all'invito per età, esclusi i solleciti




ABRUZZO - Adesione all'invito per anno



GUIDONIA - Adesione all'invito per ROUND



ESTE - Adesione corretta all'invito (%)




Relative positive predictive value for CIN2+ and CIN3+ at 1° round of HPV-based vs. cytology-based screening according to the screening policy with HPV

	Co-testing			Stand alone HPV		
	Study	CIN2+	CIN3+	Study	CIN2+	CIN3+
Triage	POBASCAM	0.95	1.03	Finnish	1.34 (1.04 - 1.72)	1.22 (0.78 - 1.92).
	ARTISTIC	0.98	1.15			
	NTCC PH1 age 25-34	0.55 (0.37-0.82)	0.24 (0.13-0.45)			
Direct referral	NTCC PH1 age 25-34	0.40 (0.23-0.66)	0.34 (0.21-0.54)	NTCC PH2 age 25-34	0.89 (0.55-1.44)	0.66 (0.31-1.40)
				NTCC PH2 age 25-34	0.80 (0.55-1.18)	0.86 (0.49-1.52)

Studio POBASCAM

Gestione donne HPV+ citologia normale



Donne 29-56

Compliance

Prima ripetizione: 82% (376/459)

**Entrambe le ripetizioni: 58%
(268/459)**

Bulkmans, Lancet 2007

Swedescreen trial – compliance to protocol

PROTOCOL:

If HPV+ and Pap- repeat HPV test after 12 months

If persistent type-specific infection referred to colposcopy.

Offered second HPV test	341	100%	
Had second HPV test	270	79.2%	
Had persistent type-specific HPV infection	119	34.9%	100%
Had colposcopy	100	29.3%	84.0%

NTCC trial phase 1 women age 25.34 yrs compliance to protocol

PROTOCOL:


If HPV+ and had normal cytology repeat HPV test and cytology after 12 months

If persistent HPV or cytology ASCUS+ referred to colposcopy.


Were HPV+ and had normal cytology	510	100%	
Had immediate colposcopy	14	2.7%	
Had second HPV and cytology test	339	66.5%	
Had persistent HPV infection or cytology ASCUS+	164	32.2%	100%
Had colposcopy	148	29.0%	90.2%



Artistic study

Clinical management and timelines according to cytology grade in screening round 1 and by study group




ARTISTIC trial Compliance to triage





Arbyn et al, Vaccine 2012

HPV- vs cytology based screening CIN3+ in 2nd round




Programma	Richiamo a 12 mesi
Abruzzo	Lettera
Guidonia	Prima fase: telefonata Seconda fase: lettera Attualmente telefonata
Reggio Emilia	Lettera + telefonata di sollecito (in seconda fase)
Torino	Lettera + telefonata di sollecito
Trento	Lettera personalizzata
Umbria	Lettera
Valcamonica	
Alta padova	Lettera
Padova	Lettera + telefonata di sollecito
Este	Lettera + telefonata di sollecito
Rovigo	Lettera + telefonata di sollecito
Adria	Lettera + telefonata di sollecito

Torino, Reggio Emilia: adesione alla ripetizione a 12 mesi

Centre	HPV positive at baseline	Compliance test repeat 1 year	HPV positive at 1 year Test repeat
Torino	1448/2476 5.9% (5.6 - 6.2)	401/442 90.7% (87.6 - 93.3)	227/401 56.6% (51.5-61.5)
Reggio Emilia	445/10339 4.3% (3.9 - 4.7)	212/263 80.6% (75.3 - 85.2)	89/212 42.0% (35.3-49.0)
Totale	1893/35100 5.4% (5.2 - 5.6)	613/705 87.0% (84.5-89.4)	316/613 51.5% (47.6-55.5)


Lettera+telefonata sollecito

VENETO - Ripetizione a 12 mesi: adesione all'invito, per programma




Lettera + telefonata sollecito

VENETO - Adesione alla ripetizione a 12 mesi, per età



VALCAMONICA - Adesione alla ripetizione a 1 anno




UMBRIA

RIPETIZIONE A 1 ANNO

Dopo 1 anno sono state richiamate
telefonicamente 128 donne e sono tornate 90
(70%)

GUIDONIA - Adesione alla ripetizione a 12 mesi per modalità di invito




ABRUZZO

RIPETIZIONE A 1 ANNO

<i>1° round 2010</i>	<i>%</i>
567 / 1372	41,30%

Lettera

Adesione alla ripetizione a 1 anno per programma



Conclusioni

- Maggiore adesione rispetto al pap test in quasi tutti i contesti
- Molto variabile la compliance al richiamo ad 1 anno. Sollecito telefonico necessario
- Quale adesione al re-screening a 5 anni?